Curated News
By: NewsRamp Editorial Staff
July 01, 2026

Onco-Innovations Secures CAD$5M Private Placement for Cancer Research

Discuss on X, formerly Twitter Discuss on Substack Discuss on Telegram participate in discussion on bluesky Participate in discussion on Mastodon View History of this news story on GitHub
Original Source

TLDR

  • Onco-Innovations secures CAD$5M funding to advance ONC010 program, potentially boosting its stock value and market position.
  • The private placement consists of 6,764,070 units at CAD$0.7392 each, with proceeds funding ONC010 development and SynoGraph platform.
  • Onco-Innovations aims to improve cancer treatment through innovative research, offering hope for better health outcomes.
  • The funding structure uses 18 monthly settlement tranches based on future share price, a unique financing approach.

Impact - Why it Matters

This news matters because it signals a critical infusion of capital into Onco-Innovations' efforts to develop novel cancer treatments. The funding will accelerate the ONC010 program and SynoGraph platform, potentially bringing new therapies to patients with solid tumors. For investors, it represents a strategic move to advance the company's pipeline, which could lead to significant value if the technology proves successful. Additionally, the structured settlement tranches align investor incentives with the company's performance, which may mitigate risk and foster long-term growth.

Summary

Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF), a Canadian-based oncology company, has announced a significant milestone in its funding journey. The firm executed a term sheet with arm's-length institutional investors for a non-brokered private placement valued at approximately CAD$5 million. The offering comprises 6,764,070 units at a notional price of CAD$0.7392 per unit, each unit consisting of one common share and one common share purchase warrant. The transaction is expected to close on or about July 15, 2026, subject to customary conditions and regulatory approvals. Under the proposed structure, the company’s economic interest will be determined through 18 monthly settlement tranches based on the future trading price of its shares, with additional details to be provided upon closing.

The proceeds from this financing are earmarked to support the development of Onco-Innovations’ ONC010 program, including manufacturing and preclinical testing activities, as well as the advancement of its SynoGraph(TM) platform and general working capital. The company is dedicated to cancer research and treatment, specializing in oncology, and holds an exclusive worldwide license to patented technology targeting solid tumours. This funding injection is crucial for moving its pipeline forward and bringing innovative solutions to the fight against cancer.

Investors can stay updated on the latest news and updates relating to ONNVF in the company’s newsroom at https://ibn.fm/ONNVF. The press release was disseminated by InvestorWire, a specialized communications platform that offers advanced wire-grade press release syndication for private and public companies. InvestorWire is part of the Dynamic Brand Portfolio @ IBN, delivering access to a vast network of wire solutions, editorial syndication to 5,000+ outlets, enhanced press release enhancement, and social media distribution to millions of followers. This comprehensive approach ensures that Onco-Innovations' message reaches a wide audience of investors, influencers, and the general public.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Onco-Innovations Secures CAD$5M Private Placement for Cancer Research

blockchain registration record for this content.